Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

Dow Jones

02/10

2219 GMT - Imaging-tech provider Pro Medicus's share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what Pro Medicus offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. "Pro Medicus provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term," Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

February 09, 2026 17:19 ET (22:19 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2610721661"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610721661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610721661?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 06:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610721661","market":"hk","top_or_hot":-1,"title":"Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2219 GMT - Imaging-tech provider <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a>'s share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"<a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 17:19 ET (22:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-02-10 06:19</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2219 GMT - Imaging-tech provider <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a>'s share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"<a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 17:19 ET (22:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"醫療保健技術","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610721661","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610721661","pubTimestamp":1770675540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2219 GMT - Imaging-tech provider Pro Medicus's share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what Pro Medicus offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"Pro Medicus provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","PME.AU":"PRO MEDICUS LTD"},"translate_title":"Pro Medicus的商业案例因人工智能的采用而更具吸引力——Market Talk","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":0.9},"content_text":"2219 GMT - Imaging-tech provider Pro Medicus's share price is plumbing 18-month lows after being caught up in the global software selloff. Morgans says investors concerned about AI threats misunderstand what Pro Medicus offers. It upgrades the stock to buy from accumulate. Analyst Iain Wilkie says AI will become one of the most powerful tools in healthcare. But for radiology it still needs stable, high-performance infrastructure to operate. \"Pro Medicus provides that infrastructure, so, in many ways the acceleration toward AI potentially makes its business case more compelling as a product versus peers--at least in the medium term,\" Morgans says. It has a A$290.00/share price target on Pro Medicus, which ended Monday at A$161.17. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 17:19 ET (22:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}